

Ankit Kansagra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/909726/publications.pdf>

Version: 2024-02-01

47
papers

1,089
citations

567281

15
h-index

434195

31
g-index

50
all docs

50
docs citations

50
times ranked

1409
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. <i>Leukemia</i> , 2019, 33, 2266-2275.	7.2	385
2	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	85
3	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2113-2123.	2.0	77
4	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 642-649.	1.2	65
5	Sporadic late-onset nemaline myopathy. <i>Neurology</i> , 2019, 93, e298-e305.	1.1	45
6	Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 28-29.	1.4	42
7	Continued Refinement of the Treatment for Light-Chain Cardiac Amyloidosis. <i>Circulation</i> , 2022, 145, 18-20.	1.6	41
8	Continuing challenges and current issues in acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 526-541.	1.3	33
9	Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1478-1484.	2.0	31
10	Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells. , 2020, 8, e000515.		27
11	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 326-335.	0.4	27
12	Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e27-e34.	3.8	25
13	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2127-2132.	2.0	21
14	Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 345-356.	2.3	21
15	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <sc>MAMMOTH</sc>. <i>American Journal of Hematology</i> , 2021, 96, E5-E8.	4.1	20
16	Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice. <i>Pharmaceutical Medicine</i> , 2022, 36, 163-171.	1.9	19
17	Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. <i>Leukemia</i> , 2022, 36, 877-880.	7.2	18
18	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. <i>A CIBMTR analysis. Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13

#	ARTICLE	IF	CITATIONS
19	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	1.2	11
20	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. <i>Blood</i> , 2018, 132, 2015-2015.	1.4	10
21	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 191, 442-452.	2.5	8
22	Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 476-487.	1.5	8
23	Second Autologous Hematopoietic Stem Cell Transplant as Salvage Therapy for Relapsed Multiple Myeloma: A Global Treatment Option for Eligible Patients. <i>Acta Haematologica</i> , 2018, 139, 45-46.	1.4	6
24	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
25	Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment. <i>Blood</i> , 2018, 132, 3233-3233.	1.4	6
26	The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement. <i>Leukemia Research</i> , 2021, 100, 106480.	0.8	5
27	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>t(8;21) KMT2A</i>-rearranged AML. <i>Blood Advances</i>, 2022, 6, 828-847.</i>	5.2	5
28	Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 26-27.	1.4	5
29	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3991-3995.	5.2	5
30	Reporting of race and ethnicity at an international haematology conference. <i>British Journal of Haematology</i> , 2020, 191, e107-e109.	2.5	4
31	Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study. <i>Diagnostics</i> , 2020, 10, 219.	2.6	3
32	Belantamab Mafadotin in Patients with Relapsed/Refractory AL Amyloidosis with Myeloma. <i>Blood</i> , 2021, 138, 1670-1670.	1.4	3
33	Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. <i>Hematological Oncology</i> , 2022, 40, 49-57.	1.7	2
34	COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with Myeloid Malignancies Than B-Cell Malignancies. <i>Blood</i> , 2021, 138, 4134-4134.	1.4	2
35	Evaluation of SARS-CoV-2 Serological Testing in Patients with Multiple Myeloma and Other Hematologic Malignancies on Monoclonal Antibody Therapies. <i>Diagnostics</i> , 2020, 10, 992.	2.6	1
36	Clinical and Molecular Characteristics Associated with Vitamin C Deficiency in Myeloid Malignancies; Real World Data from a Prospective Cohort. <i>Blood</i> , 2021, 138, 1217-1217.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Real-World Treatment Patterns and Outcomes of Patients with Functional High-Risk (Early Relapse) Multiple Myeloma. <i>Blood</i> , 2020, 136, 17-18.	1.4	1
38	The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 7-8.	1.4	1
39	HSR22-178: Real World Outcomes of Cancer Patients With SARS-CoV-2 Infection Receiving Monoclonal Antibodies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, HSR22-178.	4.9	1
40	Uncommon Disease in a Rare Location. <i>Circulation</i> , 2020, 142, 1591-1595.	1.6	0
41	Clinical Outcomes Related to the Use of Monoclonal Antibody Therapy for Steroid Refractory Acute Graft-Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 4593-4593.	1.4	0
42	Outcomes of Hospitalization for Stem Cell Transplant in Sickle Cell Disease: Are We There Yet?. <i>Blood</i> , 2018, 132, 4640-4640.	1.4	0
43	Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical Trials. <i>Blood</i> , 2018, 132, 2267-2267.	1.4	0
44	Blood and Blues: Prevalence of Mental Health Disorders in Patients Hospitalized with Acute Leukemia. <i>Blood</i> , 2018, 132, 4871-4871.	1.4	0
45	Efficacy of Treatments for Patients with Triple-Class Refractory (TCR) Multiple Myeloma (MM): Benchmark for New Agents Utilizing Real-World Data (RWD). <i>Blood</i> , 2021, 138, 3786-3786.	1.4	0
46	Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplant (ASCT) for Patients with POEMS Syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin) Tj ETQq0 0 0 rgBT / Overlock 00 Tf 50 37		
47	Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia. <i>Blood</i> , 2020, 136, 34-35.	1.4	0